Mechelen, Belgium; 12 June 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ:
GLPG) today announced that during its meeting of 12 June 2023, the Board of
Directors co-opted Dr. Susanne Schaffert as non-executive independent Director.
Dr. Schaffert replaces Dr. Rajesh Parekh who stepped down on 10 June 2023.
After an extraordinary 27-year career at Novartis in various global roles,
including commercialization, market access, investor relations, business
development & licensing, acquisitions and company integration, Dr. Schaffert
retired in 2022 as President of Novartis Oncology and Member of the Novartis
Executive Committee. In that role, Dr. Schaffert ran a global $15 billion
business across 80 countries, accelerating the internal product pipeline with
six new clinical programs, multiple global launches, and making the first CAR-T
therapy, Kymriah®, commercially available in 36 countries, including the US,
Europe, and Japan.
Dr. Schaffert is also a member of the Board of Directors of Incyte Corporation
(NASDAQ: INCY) and Novo Holdings A/S, and a member of the Novo Advisory Group
(NAG) and the Executive Education Board of St. Gallen Business School.
"On behalf of the Galapagos' Board of Directors, I am very pleased to welcome
Susanne to our Board," said Dr. Paul Stoffels(1), CEO and Chairman of Galapagos.
"Susanne brings a wealth of R&D, regulatory and commercial expertise in
oncology, and more specifically in CAR-T therapy. Her operational experience,
global network and understanding of the competitive landscape in oncology will
offer important perspectives and strategic input to our Board as we continue our
work to deliver transformational medicines to patients."
"I am very honored to join the Board of Directors of Galapagos," commented Dr.
Susanne Schaffert. "I look forward to contributing to the company's mission to
pioneer for patients and accelerate science and innovation to address important
unmet needs."
"The Board and I also want to sincerely thank Dr. Rajesh Parekh for his
invaluable contributions and commitment as former Chairman and member of the
Board of Directors during his 19-year tenure. As a co-founder and member of the
Board of Directors of Galapagos in the early days, I had the opportunity to work
with Raj, and I have always greatly appreciated his leadership and insights in
building out the company throughout the years," concluded Dr. Paul Stoffels, CEO
and Chairman of Galapagos.
About Galapagos
Galapagos is a fully integrated biotechnology company united around a single
purpose: to transform patient outcomes through life-changing science
and innovation for more years of life and quality of life. We focus on the key
therapeutic areas of immunology and oncology, where we have developed a deep
scientific expertise in multiple drug modalities, including small molecules and
cell therapies. Our portfolio comprises discovery through to commercialized
programs and our first medicine for rheumatoid arthritis and ulcerative colitis
is available in Europe and Japan. For additional information, please
visit www.glpg.com (http://www.glpg.com/) or follow us on LinkedIn
(https://www.globenewswire.com/Tracker?data=ezxJkwSFR72hjpmLV87_rCWHmXiEkJdYmJZA
mM2ogtGbwOFtqfgHUBEEFGXHaFo83cvmiDFpg4AEmLKK78dHsjgGmCaeMvJ36E2Ayj-
ezOHnYHIaUIAZlc1A0XmbkMKzClCPc7hEiPOvByRSfbsFQunjB9Mw2v2EXH653ri5widmmTRkrkre_FA
Y2bZEDq-VJC9NEfuFyUPT0A29gI-
p13O_hFuDoS9sZUqcxgX6JcnrwMRT63EZMXbky2R5cA0wPn3z0x5aqDb4BY1NBSLYewJzDF3OBhrblWA
hgWvClWvZVrI_FoJWrVp-KlQ91FztQeQrUb9bss1A59BpNVDQLuE5mW2kAbA-
lwKqe56rVnXPtYPdq2b7-
8gnY3_3Im5KOPoLjl9xR5WeSc7rBZ76O5rrd1J3p2c292_9pUauVIxKkxhwE-
JQpKN6DSA1L4EqK7XtUTAcJQw4l_jzaSKIBTNyxJDd3e4eo2KiYIn-zFqPBOqvSMIdJFYNDxr-
H4U5IzD_KAqNRLjM6QQ9ixbssNjrCtLrmd4DpeQX9EbGdypFqCboHKE2YNXgRYNzIppmf8br_LKU1eD5
fxZVMpzuFeeSpopW66cNapQM_k8YfhKBPvgRnuj06a3LGeWH2OzNwLZ4junayWghclaIgY6KtVwEXh_l
5jYtP8eUoBnsqgr5UVGRGLFPa8ZKbe20xzl_jPWftZaxCkIq8_iH2cs-oQ==) or Twitter
(https://www.globenewswire.com/Tracker?data=R498b57aPdjPPnpO80BvL5Dj20Y9F_la0Ss0
CxwYvDH8H56pXknrj_Md3DIU2_LoG9WbkunFYQ_mBbwylanRgyQA1xrVx2NE6O1MbiqeORMvKGc2yYso
qKnVQr8_LQyhOSXFgM01nLkEXHAmRH8ve5jiRThZeVD-
P95cNmE1Z6RNkXNiUEGyY89pziVjbXAGgpU0tDva-Dv9o0z80p58C-
J8fDfOMQFBY6HcSmpNclzdUyWHgdjP2ENXamg-LwvJSqCeZ1Xy4ZJA_krwQER-
lsJpuwUsO1wkBzcN7E_cPQVOvlNQ8OxyKaGqRpkxyEO8gLj9jBKPFlQ4LE1nQ2vhyjmst-
aJv2XFFvFrqvaXR5dW_4_IwYUu8MWzJa9m23v2w_zWgLD9PI30j_xCxTrugA7sOiEvHw9ALHiEjgu61T
Le-oLdpFcjekviEdsXkG-
leAzl17cVoc9YQo_yTB9FT_35A0hEm8QyAbcp5OtmFMnfLPQIRlCY5BcjeR8-
GeV13IvKT7yE8JHas4wlj4SSnE3pckT1EXou1yle_rmshbKTuIWS8VLedeuzxQT_TxgUMl5CbUmYtCRf
yXpUoqzPtfXywFbemSlAQt_7oPCcbm082dOus_7a-
0GpaCdE2tatiaUScKEYInlUFYco8vSRm1VUREUk3b9UhM9edL9C3BN0PU2f9-0n1GToRrvrW1htdBJg3
Eafs7tjYALDBZp9sQ==).
Contacts

  Media relations contact                    Investor relations contact
  Marieke Vermeersch                         Sofie Van Gijsel
  +32 479 490 603                            +1 781 296 1143
  media@glpg.com (mailto:media@glpg.com)
                                             Sandra Cauwenberghs
                                             +32 495 58 46 63
                                             ir@glpg.com (mailto:ir@glpg.com)

Forward-looking statements
This press release includes forward-looking statements, all of which involve
certain risks and uncertainties. These statements are often, but not always,
made through the use of words or phrases such as "will," "continue," "forward,"
and any similar expressions. These statements include, but are not limited to,
statements regarding the appointment of a new director. Any forward-looking
statements in this press release are based on our management's current
expectations and beliefs, and are not guarantees of future performance. Forward-
looking statements may involve unknown and known risks, uncertainties and other
factors which might cause our actual results, performance, or achievements to be
materially different from any historic or future results, performance, or
achievements expressed or implied by such statements. These risks, uncertainties
and other factors include, without limitation, the risk that we may not be able
to realize the expected benefits from the appointment of the new director. A
further list and description of these risks, uncertainties and other factors can
be found in our filings and reports with the Securities and Exchange Commission
(SEC), including in our most recent annual report on Form 20-F filed with the
SEC, as supplemented and/or modified by any other filings and reports that we
have made or will make with the SEC in the future. Given these risks and
uncertainties, the reader is advised not to place any undue reliance on such
forward-looking statements. In addition, even if our results, performance, or
achievements are consistent with such forward-looking statements, they may not
be predictive of results, performance, or achievements in future periods. These
forward-looking statements speak only as of the date of publication of this
press release. We expressly disclaim any obligation to update any forward-
looking statements in this press release, unless required by law or regulation.
--------------------------------------------------------------------------------
(1 )Throughout this press release, 'Dr. Paul Stoffels' should be read as 'Dr. Paul Stoffels, acting via Stoffels IMC BV'
Â